Your session is about to expire
← Back to Search
This trial is testing how well radiation therapy, plasma exchange, and either pembrolizumab or nivolumab work in treating patients with melanoma.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You are currently taking a biotin supplement.You are currently pregnant or breastfeeding.You are able to have children but are not willing to use effective birth control during the study.You have a medical condition that can or cannot be measured.
- Group 1: Treatment (radiation therapy, plasma exchange, immunotherapy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Pembrolizumab been examined in any other research projects?
"Currently, 1633 studies are in progress studying Pembrolizumab with 200 of them being Phase 3 trials. Houston, Texas is a major centre for these clinical investigations but there are over 73,000 sites conducting experiments concerning this medication worldwide."
What goals is this research attempting to achieve?
"The principal outcome that will be monitored for up to 24 months is the feasibility of this treatment regimen. Secondary objectives include assessing progression-free survival, overall response rate and overall survival via Kaplan-Meier estimates."
What is the cap on the number of participants in this medical experiment?
"Yes, the information on clinicaltrials.gov affirms that this scientific exploration is currently accepting applicants. It was initially advertised in December of 2020 and most recently updated in May 2022. The experiment is accommodating 20 subjects across a single site."
What indications is Pembrolizumab routinely prescribed for?
"Pembrolizumab is a viable treatment for unresectable melanoma, as well as microsatellite instability high and squamous cell carcinomae melanoma, as well as microsatellite instability high and squamous cell carcinoma cases with a heightened risk of recurrence."
Does this clinical experiment currently admit participants?
"Per the data posted on clinicaltrials.gov, this study is actively enrolling participants and has been since December 14th 2020 (latest update - 5 May 2022)."
Share this study with friends